Certis Oncology Solutions is a company that specializes in providing advanced molecular and immune profiling services for oncology. Their services are aimed at supporting precision medicine in cancer treatment, offering comprehensive genomic profiling to help guide treatment decisions.

Certis Oncology Solutions is a life science technology company with a mission to realize the promise of precision oncology. Our product is Oncology Intelligence™— highly predictive therapeutic response data derived from proprietary biological models of cancer. We apply these models to machine learning and AI-enhanced predictive algorithms, the development of the next generation of targeted cancer therapeutics, and functional precision medicine.

Established in 2016, Certis began its journey in functional precision oncology, helping cancer patients and their oncologists through YourPDX™ testing.

ACCELERATING THE DEVELOPMENT OF NEW CANCER THERAPIES
Certis partners with therapeutic developers to help close the problematic translational gap between preclinical studies and clinical trials. Through clinically relevant, well-characterized and annotated cancer models, advanced imaging technology, including x-ray irradiation with image-guided radiation therapy, and thoughtfully designed custom studies, our proprietary platform can bring greater certainty to go/no-go drug development decisions.

We are committed to providing translationally relevant preclinical models to drug developers for efficient and effective transition into the clinic.  Learn more about our preclinical oncology services.

Certis Oncology Solutions, Inc.

Certis Oncology announces closing of $10 million Series C fundraising round and names John R. Tozzi as new board chairman. Read the full press release now: https://hubs.la/Q02gPk9h0. #SeriesC #Fundraising #NewBoardMember #CancerResearch #LifesSciences #FightCancerTogether

Did you miss our recent talk on animal welfare in the preclinical CRO space? Register now to watch the full webinar recording hosted by Inside Scientific: https://hubs.la/Q02jc1Jc0. #CancerResearch #3Rs #AnimalWelfare #MouseModels #CancerModels #TranslationalResearch #FightCancer #CertaintySavesLives 

Stop by a Live Certis Poster Session Today at the 8th Annual Tumor Models San Francisco Summit! 
The Certis Team will present “In Vivo Tumor Implantation Site Exhibits Differential Immune Response in Solid Tumors” on Wednesday, January 31, at 4:50pm (PST). This upcoming poster presentation demonstrates differences in the tumor microenvironment, overall immune response, and the pharmacological outcome, between subcutaneous and orthotopic humanized PDX models using peripheral blood mononuclear cells. This sample figure shows a pathway enrichment analysis of top differentially expressed genes between subcutaneous and orthotopic tissue of PDX models that may functionally contribute to differences in therapy response.  

Find Your Model Match at the Certis Exhibitor Booth
Talk to us about your unique cancer model needs at the upcoming Tumor Models SF Summit! Finding the right preclinical models to evaluate efficacy and understand the complex mechanisms of action induced by your targeting compound(s) can be challenging. A strategic translational approach – combining the predictive power of artificial intelligence with advanced PDX and PDX-derived models – can accelerate your preclinical program. The cancer model database includes 56 unique PDX models and companion PDX-derived 3D cell cultures with the most common RAS mutations in cancer, including lung, colorectal, and pancreatic. Download the data pack now: https://hubs.la/Q02gjHBm0. #TMSF24 #TumorModels #WestCoastBioPharma #TranslationGap #CancerResearch #FightCancer #RareCancers #MetastaticCancers #CertaintySavesLives #CancerArtificialIntelligence #AI #IO #DrugDevelopment #DrugDiscovery  

COM:CERTISONCOLOGY

Certis Oncology Solutions

Analysis Not Available